ArticleProgress in biomaterials2018
Immunoisolation of stem cells by simultaneous encapsulation and PEGylation.
Article in Progress in biomaterials, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 10 citations in OpenAlex.
- Evolving Cell-Based and Cell-Free Clinical Strategies for Treating Severe Human Liver Diseases.Cells · 2020Review
- Insulin-Producing Cell Transplantation Platform for Veterinary Practice.Frontiers in veterinary science · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Today, cell therapy is known as an important tool in the treatment of chronic diseases where cells lose their normal function. Immunoisolation systems using microencapsulation or PEGylation have been developed to evade the problem of rejection by the immune system. The aim of the present study was to investigate a combination of microencapsulation and PEGylation methods in coating mouse embryonic stem cells (mESCs) to determine its effect in reducing the host's immune response. Therefore, methoxy polyethylene glycol (mPEG) binding on alginate-trimethyl chitosan (TMC) microcapsules was investigated using FTIR. Furthermore, survival of the microencapsulated mESCs was confirmed using AO/PI staining and MTT assays. In addition, the effect of mESCs co-cultured with foreign lymphocytes was evaluated. Overall, interleukin-2 (IL-2) secretions as a response of the immune system revealed that mESCs microencapsulation in alginate-TMC-PEG, reduced the immune system response. The results suggested that IL-2 secretion was reduced to 62% at seventh day.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.